Catherine Yaussy
Gastroenterology · Dallas, TXNPI 1487614749
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 603 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by AbbVie at 37.0% of the total. Reporting peaked in 2023 at $2,644 and has fallen 99.3% since, to $19 in 2024.
Across 603 payments — averaging $16.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Bristol Myers Squibb$1K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Johnson & Johnson$884
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$605
- Ferring Pharmaceuticals Inc.$330
- plus $2K from 20 others
What the payments were for
- Food & beverage$10,015100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 217 | $3,707 |
| Bristol Myers Squibb | 115 | $1,484 |
| Takeda Pharmaceuticals U.S.A., Inc. | 53 | $1,009 |
| Johnson & Johnson(2 entities) | 63 | $884 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 34 | $605 |
| Ferring Pharmaceuticals Inc. | 18 | $330 |
| Merck | 11 | $301 |
| QOL Medical, LLC | 16 | $265 |
| Pfizer | 17 | $258 |
| Ironwood Pharmaceuticals, Inc | 9 | $181 |
| Intercept Pharmaceuticals, Inc. | 8 | $166 |
| Nestle Healthcare Nutrition Inc. | 7 | $111 |
| Daiichi Sankyo Inc. | 5 | $108 |
| Regeneron Healthcare Solutions, Inc. | 5 | $107 |
| Redhill Biopharma Inc. | 4 | $76 |
| Braintree Laboratories, Inc. | 5 | $71 |
| E.r. Squibb & Sons, L.L.C. | 1 | $71 |
| Micro-tech Endoscopy USA, Inc. | 2 | $64 |
| Sanofi | 2 | $49 |
| Shire North American Group Inc | 3 | $48 |
| Evoke Pharma, Inc. | 3 | $41 |
| Shionogi Inc | 1 | $21 |
| AstraZeneca | 1 | $20 |
| Ardelyx, Inc. | 1 | $17 |
| Endo Pharmaceuticals Inc. | 1 | $13 |
| UCB, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,015 in reported general payments places this provider in the 80th percentile of 1,350 gastroenterology providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Omeprazole | 100 | $1,219 |
| Pantoprazole Sodium | 40 | $548 |
| Dicyclomine Hcl | 15 | $191 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Dallas
- John FordtranDallas$9.9M
- Michael BrownDallas$5.5M
- Parvez MantryDallas$958K
- Jay HortonDallas$326K
- Jacqueline O LearyDallas$157K
- Sami ArslanlarDallas$142K
- Amit DesaiDallas$71K
- Byron CryerDallas$68K
- Bincy AbrahamHouston$1.6M
- Mazen NoureddinHouston$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.